@medbed.techologyn: 🚨 IVERMECTIN + FENBENDAZOLE: A Cancer Survivor’s Story A 59-year-old man from Liverpool was diagnosed with Stage 4 prostate cancer that had already metastasized to his lungs and spine. His PSA level measured 79, indicating an advanced and aggressive disease. Facing limited options, he chose to explore an unconventional path alongside standard medical treatment. He began taking Fenbendazole and Ivermectin — two antiparasitic drugs that have gained attention for their potential anticancer properties. His regimen reportedly included Fenbendazole (~1000 mg, three times per week) and Ivermectin (12 mg daily, roughly 0.2 mg/kg), while he continued to follow his doctor’s guidance and monitored his progress closely. Within four months, his PSA level dropped from 79 to 0.32, and scans showed a reduction in lesions affecting his lungs and spine. Throughout this period, he reported minimal side effects and was able to maintain a normal daily routine. While this case is remarkable, it remains an isolated anecdote rather than scientific proof. Other factors — such as concurrent treatments, diet, supplements, or natural variability — could have played a role. Still, stories like this highlight why researchers are investigating drug repurposing as a possible avenue in cancer therapy. For more details contact us using our emails address below [email protected] #Fenbendazole #Ivermectin #medbed

Medbed techologynews

Open In TikTok:

Region: US

Friday 20 March 2026 08:53:59 GMT